2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Recurrent Childhood Visual Pathway and Hypothalamic Glioma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Recurrent Childhood Visual Pathway and Hypothalamic Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
Cilengitide National Cancer Institute (NCI) | Phase 2 | B |
Eloxatin National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM City of Hope Medical Center | Phase 1 | CCC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CCC |
View all 20 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →